The initial public offering (IPO) of Anthem Biosciences Limited has been fully subscribed on Day 2. The offer is attracting investor interest across all the segments. (Photo: Social)
The initial public offering (IPO) of Anthem Biosciences Limited has been fully subscribed on Day 2. The offer is attracting investor interest across all the segments. The public issue was of ₹3,395 crore, which opened on July 14, 2025 and will remain open for bidding until July 16, 2025.
Subscription Status on Day 2
As of the second day of bidding, the IPO has been subscribed 1.13 times overall. Key subscription data includes:
• Retail Investors: 0.87x
• Qualified Institutional Buyers (QIBs): 0.37x
• Non-Institutional Investors (NIIs): 2.74x
The strong demand from NIIs indicates growing confidence in the company’s long-term prospects, even as institutional buying remains in early stages.
The details about the IPO are hereunder:
• Price Band Per Share: ₹540–₹570
• Minimum Investment Required: ₹14,040
• Lot size: 26 shares
• Maximum Lot: 13
• Bid Opening Date: July 14, 2025
• Bid Closing Date: July 16, 2025
• Allotment date: July 17, 2025
• Listing Date: July 21, 2025
Anthem Biosciences Limited -Company Background
Anthem Biosciences Limited operates as a Contract Research, Development & Manufacturing Organization serving pharmaceutical companies, globally. The company provides end-to-end drug development and manufacturing services to its clients.
The company was founded in 2006 and has it headquarter in Bangalore. Anthem Biosciences Limited is driven by innovation and technology, focused on contract research, development, and manufacturing.
The company operates in drug discovery, development, and manufacturing. It is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities.
Anthem Biosciences’ clients include innovation-focused emerging biotech and large pharmaceutical companies that operate globally.
(Disclaimer: This article is for informational purposes only and should not be construed as investment advice. Before making any investment, conduct thorough research and consult a financial advisor.)
Also Read: Upcoming IPOs Next Week: Anthem Biosciences, Spunweb Nonwoven Ltd; Check Out The List Here
Ankur Mishra is a journalist who covers an extensive range of news, from business, stock markets, IPOs to geopolitics, world affairs, international crises, and general news. With over a decade of experience in the business domain, Ankur has been associated with some of the reputed media brands. Through a sharp eye on global marketplaces along with deep insights and analysis of business strategies, Ankur brings simplicity to the complex economic matrix to decode market trends and empower people.
He is committed to entrenched data, facts, research, solutions, and a dedication to value-based journalism. He has covered trade tariff wars, international alliances, corporate policies, government initiatives, regulatory developments, along with micro- and macroeconomic shifts impacting global fiscal dynamics.
Guillermo del Toro returned to Cannes with a 4K restoration of Pan’s Labyrinth, reflecting on…
Prateek Yadav Death Reason: How Did Mulayam Singh Yadav’s Son And Aparna Yadav’s Husband Die?
Prateek Yadav, the younger son of Mulayam Singh Yadav and stepbrother of Akhilesh Yadav, passed…
Stock market outlook today, May 13: Sensex and Nifty remain under pressure after Tuesday’s massive…
